
CLAIMS

1. A method for treating or preventing atherosclerosis in a mammal, comprising:

providing an agent for inhibiting interaction
between P-selectin and a ligand of P-selectin, and
administering said agent to a mammal in need of such
treatment to cause such inhibition to occur.

- 2. The method of claim 1 wherein said P-selectin is on a cell.
- 3. The method of claim 2 wherein said cell is an endothelial cell.
- 4. The method of claim 2 wherein said cell is a platelet.
- 5. The method of claim 1 wherein said ligand comprises a carbohydrate.
- 6. The method of claim 1 wherein said ligand comprises a glycoprotein.
- 7. The method of claim 1 wherein said ligand is selected from the group consisting of sialyl-Lewis x, sialyl-Lewis a, sialyl-Lewis x-pentasaccharide, polylactosaminoglycan, carbohydrate containing 2,6 sialic acid, Lewis x 3'-0-sulfate, heparin oligosaccharides, PSGL-1, 160 kD monospecific P-selectin ligand and lysosomal membrane glycoproteins.
- 8. The method of claim 1 wherein said ligand is on a cell selected from the group consisting of monocytes, neutrophils, eosinophils, CD4⁺ T cells, CD8⁺ T cells, and natural killer cells.



- 9. The method of claim 1 wherein said ligand is on a leukocyte.
- 10. The method of claim 9 wherein said leukocyte is a neutrophil.
- 11. The method of claim 9 wherein said levkocyte is a monocyte.
- 12. The method of claim 1 wherein said P-selectin can bind to said ligand in the absence of said agent.
- 13. The method of claim 1 wherein said agent is selected from the group consisting of a soluble form of at least a portion of said P-selectin and a soluble form of at least a portion of said ligand and mixtures thereof.
- 14. The method of claim 1 wherein said agent is an inhibitory protein.
- 15. The method of claim 14 wherein said inhibitory protein is selected from the group consisting of an antibody against at least a portion of said P-selectin and an antibody against at least a portion of said ligand and mixtures thereof.
- 16. The method of claim 15 wherein said antibody is a monoclonal antibody.
- 17. The method of claim 1 wherein said agent is an inhibitory peptide.

- 18. The method of claim 17 wherein said P-selectin has a first binding site for said ligand and said ligand has a second binding site for said P-selectin, and wherein said inhibitory peptide is a peptide selected from the group consisting of at least a portion of said first binding site and at least a portion of said second binding site and mixtures thereof.
- 19. The method of claim 1 wherein said agent is an inhibitory carbohydrate.
- 20. The method of claim 19 wherein said inhibitory carbohydrate is selected from the group consisting of sialyl-Lewis x and its analogs, sialyl Lewis a and its analogs, heparin oligosaccharides and carbohydrates containing 2,6 sialic acid.
- 21. The method of claim/1 wherein said agent is an inhibitory glycoprotein.
- 22. The method of claim 21 wherein said inhibitory glycoprotein is selected from the group consisting of PSGL-1, 160 kD monospecific P-selectin ligand, lysosomal membrane glycoprotein and glycoprotein containing sialyl-Lewis x.
- 23. The method of claim 1 wherein said agent is an inhibitory sulfatide.
- 24. The method of claim 1 wherein said agent is selected from the group consisting of an analog of said P-selectin and an analog of said ligand and mixtures thereof.
- 25. The method of claim I wherein said agent is a substance derived from snake venom or a plant extract.

- 26. The method of claim 1 wherein said agent is an inhibitor of granular release.
- 27. The method of claim 1 wherein said agent is an inhibitor of a molecule required for the synthesis, post-translational modification or functioning of said P-selectin or said ligand.
- 28. The method of claim 1 wherein said agent inhibits interaction between said P-selectin and said ligand so as to at least partially prevent formation of an atherosclerotic fatty streak.
- 29. The method of claim 1 wherein said agent inhibits interaction between said P-selectin and said ligand so as to at least partially prevent formation of an atherosclerotic intermediate lesion.
- 30. The method of claim 1 wherein said agent inhibits interaction between said P-selectin and said ligand so as to at least partially prevent formation of an atherosclerotic fibrous plaque.
- 31. The method of claim 1 wherein said agent inhibits interaction between said P-selectin and said ligand so as to at least partially prevent growth of an atherosclerotic lesion after a surgical procedure for at least partially preventing restenosis.
- 32. The method of claim 1 wherein said agent inhibits interaction between said P-selectin and said ligand so as to at least partially reverse a formed atherosclerotic fatty streak.



- 33. The method of claim 1 wherein said agent inhibits interaction between said P-selectin and said ligand so as to at least partially reverse a formed atherosclerotic intermediate lesion.
- 34. The method of claim 1 wherein said agent inhibits interaction between said P-selectin and said ligand so as to at least partially reverse a formed atherosclerotic fibrous plaque.
- 35. The method of claim 1 wherein said administering occurs prior to formation of an atherosclerotic lesion.
- 36. The method of claim 1 wherein said administering occurs subsequent to formation of an atherosclerotic lesion.
 - 37. The method of claim 1 wherein said mammal is a human.
- 38. A therapeutic agent in a dosage form and concentration suitable for treating or preventing atherosclerosis in a mammal in need of such treatment, said agent being effective to inhibit interaction between P-selectin and a ligand of P-selectin.

add S

add Cal